The price-to-earnings ratio for Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is 2.74x, which is above its average ratio. Moreover, the 36-month beta value for AMLX is -0.65. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AMLX is 47.09M and currently, short sellers hold a 13.83% of that float. On May 09, 2024, AMLX’s average trading volume was 3.47M shares.
AMLX) stock’s latest price update
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) has seen a decline in its stock price by -2.03 in relation to its previous close of 1.97. Zacks Investment Research reported 2024-04-04 that Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.
AMLX’s Market Performance
Amylyx Pharmaceuticals Inc (AMLX) has experienced a 0.00% fall in stock performance for the past week, with a -27.72% drop in the past month, and a -87.24% drop in the past quarter. The volatility ratio for the week is 5.51%, and the volatility levels for the past 30 days are at 7.36% for AMLX. The simple moving average for the past 20 days is -2.92% for AMLX’s stock, with a -86.44% simple moving average for the past 200 days.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with Mizuho repeating the rating for AMLX by listing it as a “Neutral.” The predicted price for AMLX in the upcoming period, according to Mizuho is $4 based on the research report published on March 18, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $4, previously predicting the price at $37. The rating they have provided for AMLX stocks is “Neutral” according to the report published on March 11th, 2024.
Leerink Partners gave a rating of “Market Perform” to AMLX, setting the target price at $4 in the report published on March 11th of the current year.
AMLX Trading at -62.37% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.67% of loss for the given period.
Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 5.51%, as shares sank -21.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -89.84% lower at present.
During the last 5 trading sessions, AMLX remain unchanged, which changed the moving average for the period of 200-days by -91.58% in comparison to the 20-day moving average, which settled at $1.9615. In addition, Amylyx Pharmaceuticals Inc saw -86.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from Klee Justin B., who sale 4,135 shares at the price of $18.73 back on Mar 05 ’24. After this action, Klee Justin B. now owns 2,959,308 shares of Amylyx Pharmaceuticals Inc, valued at $77,440 using the latest closing price.
Cohen Joshua B, the Co-Chief Executive Officer of Amylyx Pharmaceuticals Inc, sale 4,135 shares at $18.73 during a trade that took place back on Mar 05 ’24, which means that Cohen Joshua B is holding 3,023,002 shares at $77,440 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.93 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at 0.13. The total capital return value is set at 0.09. Equity return is now at value 12.73, with 10.84 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 2.81. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.23.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at -4.18. When we switch over and look at the enterprise to sales, we see a ratio of -0.09. The receivables turnover for the company is 9.51for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.66.
Conclusion
To wrap up, the performance of Amylyx Pharmaceuticals Inc (AMLX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
